Cellular Phenotyping in Human iPSCs


Event details

Date 28.09.2021  
Category Call for proposal
Event Language English
Aim: This program will support phenotyping of human induced pluripotent stem cells (iPSCs) from our Parkinson’s Progression Markers Initiative (PPMI). Such work will facilitate future mechanistic studies and expedite drug screening and proof-of-concept testing for Parkinson’s therapeutics.
PPMI has generated and distributed iPSCs from a subset of its participants. These cell lines are coupled with robust clinical, imaging and biological data captured in the study. Recently, MJFF-funded scientists completed deep molecular phenotyping studies in dopaminergic neurons derived from these iPSCs. That data is also available.
This funding program aims to incorporate other molecular and functional phenotypic assays to further characterize the iPSCs/iPSC-derived cells from PPMI. Researchers from public and private institutions are encouraged to apply and to collaborate.
Program Priorities:
  • Assessments of known PD targets and pathophysiologic pathways
  • Assays to characterize functional, electrophysiological and/or neuroanatomical phenotypes
  • Assays/endpoints that can be compared to biofluid data to determine the value of iPSCs as human disease models
  • Comparative assessments across different cell types (e.g., neurons, glia)
  • Assessments in co-culture systems to study cell autonomous and non-cell-autonomous phenotypes
  • Contribution of aging to PD-relevant phenotypes
  • Analyses of FOUNDIN-PD data
  • Applicants may request budgets ranging from $40,000 to $200,000 for analysis of existing datasets from the PPMI iPSC sub-study and up to $1,000,000 for phenotypic analysis.
  • Requested budget amount will not correlate with prioritization for funding. Requested support should be commensurate with work proposed and must include clear explanation of costs.
Duration: Up to 2 years
  • Pre-Proposals Due: September 28th, 2021 5 p.m. US EST
  • Full Proposals Due (by invite only): January 13th, 2022 5 p.m. US EST
  • Applicants are encouraged to apply early to allow adequate time to correct errors found during the submission process.
  • Assays that are high-throughput or quantitative for PD relevant phenotypes
  • Funded groups must work together to compare protocols and align on QC markers so data generated across lines and across teams can be compared to one another
  • Teams are encouraged to deposit their differentiation protocols on protocols.io
  • Teams must adhere to the PPMI data and sample use policies
  • Teams must agree to deposit data back into LONI
  • Teams are expected to work closely with MJFF and the FOUNDIN-PD group to support updates to the data portals and data browsers
  • Teams will consult with the relevant members of the PPMI SC to promote best practices in use and interpretation of PPMI data
  • Teams must be willing to participate in quarterly calls to provide updates on their study
Eligibility: Applications may be submitted by researchers or clinicians in:
  • U.S. and non-U.S. biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities; and
  • U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.
  • Post-doctoral fellows are eligible to apply as co-investigators only and with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research. The administrative co-PI will be responsible for assisting in providing all institutional documents required for the project and will be required to sign any award contract. Training or mentoring-only proposals will not be considered.
  • As programs may require many kinds of expertise, MJFF encourages industry and academic collaborations when appropriate.
How to Apply: For Further Information:

Practical information

  • General public
  • Free


  • The Research Office


Parkinson's Disease iPSC dopaminergic neuron LRRK2 GBA SNCA

Event broadcasted in